All Professor Paul Morgan articles
-
ArticleDeveloping donanemab - balancing cost versus benefit
This article summarises recent regulatory developments surrounding the Alzheimerâs treatment donanemab and considers the future therapeutic market for this disease.
-
NewsAlzheimerâs drug milestone âbittersweetâ for certain patients
The first new dementia medicine to be licensed in over two decades shows for first time, that the course of Alzheimer disease can be modified and slow cognitive decline.